Dr. Reddy's launches Vigabatrin tablets in US market

03 Feb 2021 Evaluate

Dr. Reddy's Laboratories has launched Vigabatrin tablets, an antiepileptic drug, in the US market. The company has launched the drug in the American market after receiving approval from the US Food and Drug Administration (USFDA). This product has been designated as a Competitive Generic Therapy (CGT) by the FDA.

With a CGT designation, the company has a 180-day CGT exclusivity to market this product. The company's product is a generic version of Sabril tablets. As per the IMS Health data, the Sabril brand and its generics had sales of around $141 million for the most recent 12 months ending December last year.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1275.05 -1.95 (-0.15%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×